Literature DB >> 22116949

First trimester serum angiogenic/anti-angiogenic status in twin pregnancies: relationship with assisted reproduction technology.

O Sánchez1, E Llurba, G Marsal, C Domínguez, C Aulesa, M A Sánchez-Durán, M M Goya, J Alijotas-Reig, E Carreras, L Cabero.   

Abstract

BACKGROUND: The risk of pre-eclampsia (PE) increases in twin pregnancies, especially when assisted reproduction technologies (ART) are used. The aim of this study was to assess angiogenic/anti-angiogenic factors in maternal serum in the first trimester of twin pregnancies and establish if the mode of conception influences angiogenic status.
METHODS: This prospective study enrolled women with twin (n = 61) and singleton (n = 50) pregnancies. Dichorionic twin pregnancies were divided into two groups according to their mode of conception. Singleton pregnancies were used as the control group. Soluble fms-like tyrosine kinase (sFlt-1), free placental growth factor (PlGF) and soluble endoglin (sEng) concentrations were measured in the first trimester maternal serum.
RESULTS: In the first trimester, women with twin pregnancies had higher serum concentrations of the anti-angiogenic factor sFlt-1 than that with singleton pregnancies (3924 ± 250 versus 2426 ± 162 pg/ml, respectively; P < 0.001). Maternal serum PlGF concentrations were lower in singleton pregnancies than those in twin pregnancies (37 ± 3.7 versus 59 ± 5.6, respectively; P < 0.001). Serum concentrations of sFlt-1 were higher in twin pregnancies conceived by ART than those in spontaneous twin pregnancies (4313 ± 389 versus 3522 ± 300 pg/ml, respectively; P < 0.05). No differences between groups were observed for sEng.
CONCLUSIONS: In the first trimester, twin pregnancies conceived using ART showed a heightened anti-angiogenic status that could explain the increased risk of PE in these cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116949     DOI: 10.1093/humrep/der394

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Assisted reproductive technologies induce temporally specific placental defects and the preeclampsia risk marker sFLT1 in mouse.

Authors:  Lisa A Vrooman; Eric A Rhon-Calderon; Olivia Y Chao; Duy K Nguyen; Laren Narapareddy; Asha K Dahiya; Mary E Putt; Richard M Schultz; Marisa S Bartolomei
Journal:  Development       Date:  2020-05-29       Impact factor: 6.868

2.  The role of angiogenic markers in adverse perinatal outcomes: fresh versus frozen embryo transfers.

Authors:  Irene Woo; Yen Chan; Intira Sriprasert; Kristin Louie; Sue Ingles; Frank Stanczyk; Lynda K McGinnis; Karine Chung
Journal:  J Assist Reprod Genet       Date:  2017-09-04       Impact factor: 3.412

3.  Maternal circulating angiogenic factors in twin and singleton pregnancies.

Authors:  Jessica M Faupel-Badger; Thomas F McElrath; Michele Lauria; Lauren C Houghton; Kee-Hak Lim; Samuel Parry; David Cantonwine; Gabriel Lai; S Ananth Karumanchi; Robert N Hoover; Rebecca Troisi
Journal:  Am J Obstet Gynecol       Date:  2014-11-27       Impact factor: 8.661

4.  Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational study.

Authors:  Kyung Uk Sung; Jeong A Roh; Kyung Jin Eoh; Eui Hyeok Kim
Journal:  Obstet Gynecol Sci       Date:  2017-03-16

Review 5.  Maternal Serum Placental Growth Factor, Soluble Fms-Like Tyrosine Kinase-1, and Soluble Endoglin in Twin Gestations and the Risk of Preeclampsia-A Systematic Review.

Authors:  Katarzyna Kosinska-Kaczynska; Magdalena Zgliczynska; Szymon Kozlowski; Lukasz Wicherek
Journal:  J Clin Med       Date:  2020-01-09       Impact factor: 4.241

6.  sFlt-1, Not PlGF, Is Related to Twin Gestation Choronicity in the First and Third Trimesters of Pregnancy.

Authors:  Szymon Kozłowski; Anna Stelmaszczyk-Emmel; Iwona Szymusik; Aleksandra Saletra-Bielińska; Robert Brawura-Biskupski-Samaha; Paweł Pietruski; Agnieszka Osińska; Katarzyna Kosińska-Kaczyńska
Journal:  Diagnostics (Basel)       Date:  2021-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.